1. Phytotherapeutics


Helixmith is dedicated in inventing and commercializing
plant-based pharmaceuticals and nutraceutical.​





Inflammatory Bowel DiseaseHX204

IBD (Inflammatory Bowel Disease) is a complex disease characterized by chronic or recurring inflammation in the gastrointestinal tract. IBD is distinguished as either UC (Ulcerative Colitis) or CD (Crohn’s Disease) and requires a lifetime treatment as they are chronic upon first occurrence. ​

Approximately one-third of IBD patients’ disease severity will escalate from being moderate to severe within 10 years and 10~15% of them undergo a colectomy.

Global IBD patient population was 4.86 million in 2016, 30% of which was from the United States (1.40 million). On the other hand, Korea’s IBD population is rapidly increasing. According to Health Insurance Review & Assessment Service, IBD patient population in Korea increased sharply by 33% from 49,593 patients in 2014 to 66,267 patients in 2018.

There are currently no effective treatment for curing IBD due to lack of efficacy, intolerable adverse effects, and higher costs. Therefore, IBD remains to be an area with huge unmet medical needs.

HX204 was discovered by screening dozens of natural products that are traditionally known to improve bowel diseases. Selected products showed its effectiveness in improving tight junction and mucus secretion within the bowel along with remarkable anti-inflammatory effect.

HX204 is currently under pre-clinical development and is expected to enter clinical phase in 2022.


  • Healthy

    The intestine is clean and is pink colored

  • Ulcerative Colitis (UC)

    Inflammation is present only in the innermost layer of the lining of the colon

  • Crohn’s Disease (CD)

    Inflammation may reach through the multiple layers of the walls of the GI tract.​


There is currently no cure for IBD. Korea’s IBD drug market has grown from 68.6 billion KRW in 2013 to 142 billion KRW in 2018 (CAGR 15.6%). Global IBD market was over 9 billion USD in 2017, which the United States occupied 50% and Europe occupied 30%.

Using natural substances that provide easier approach to multiple etiological causes, Helixmith intends to develop innovative phytotherapeutics that are safe and effective for long term use. ​

Development Status​


Indication Pre-clinical Phase 1 Phase 2 Phase 3 Approval and market launch​
Inflammatory Bowel Disease (HX204)